miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma

Abstract Both miR-193a-3p and T-Cell Leukemia/Lymphoma 1 (TCL1) are enriched in the PI3K/AKT signaling pathway, which is pivotal for the regulation of the initiation and progression of diffuse large B-cell lymphoma (DLBCL). Although miR-193a-3p has been demonstrated to exert an inhibitory effect in...

Full description

Saved in:
Bibliographic Details
Main Authors: Haixia Gao, Mengbo Wang, Shuchen Xiong, Ran Zhang, Cancan Wang, Huan Zhang, Wenli Ji, Cuicui Wang, Zhiying Jia, Xinxia Li
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Journal of Translational Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12967-025-06689-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849234785031946240
author Haixia Gao
Mengbo Wang
Shuchen Xiong
Ran Zhang
Cancan Wang
Huan Zhang
Wenli Ji
Cuicui Wang
Zhiying Jia
Xinxia Li
author_facet Haixia Gao
Mengbo Wang
Shuchen Xiong
Ran Zhang
Cancan Wang
Huan Zhang
Wenli Ji
Cuicui Wang
Zhiying Jia
Xinxia Li
author_sort Haixia Gao
collection DOAJ
description Abstract Both miR-193a-3p and T-Cell Leukemia/Lymphoma 1 (TCL1) are enriched in the PI3K/AKT signaling pathway, which is pivotal for the regulation of the initiation and progression of diffuse large B-cell lymphoma (DLBCL). Although miR-193a-3p has been demonstrated to exert an inhibitory effect in various tumors, the relationship between miR-193a-3p and TCL1, as well as the mechanisms by which miR-193a-3p participates in the modulation of DLBCL onset and progression, remain to be elucidated. The expression levels of miR-193a-3p and TCL1 in DLBCL cells were examined using quantitative real-time polymerase chain reaction (qRT-PCR), and their impact on DLBCL cell growth was assessed through cell proliferation assays and flow cytometry. Subsequently, the interaction between miR-193a-3p and TCL1 was investigated using a dual-luciferase reporter assay. A nude mouse model of subcutaneous DLBCL was established in which the mice were injected with miR-193a-3p agomir, and were evaluated after 45 days. Finally, the mechanism by which miR-193a-3p modulates the PI3K/AKT signaling pathway was explored via qRT-PCR and Western blotting analyses. It was found that miR-193a-3p is downregulated, while TCL1 is upregulated in DLBCL. miR-193a-3p was shown to inhibit proliferation and induce apoptosis in DLBCL cells, in contrast to TCL1, which promotes proliferation and suppresses apoptosis. Moreover, TCL1 was identified as a target gene of miR-193a-3p. Additionally, it was demonstrated that miR-193a-3p regulates the PI3K/AKT signaling pathway through TCL1 both in vitro and in vivo. Collectively, these findings indicate that miR-193a-3p suppresses the growth of DLBCL by targeting TCL1 within the PI3K/AKT signaling pathway.
format Article
id doaj-art-992da6db48ec4f038b807fa3e2c19dd5
institution Kabale University
issn 1479-5876
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series Journal of Translational Medicine
spelling doaj-art-992da6db48ec4f038b807fa3e2c19dd52025-08-20T04:03:01ZengBMCJournal of Translational Medicine1479-58762025-07-0123111210.1186/s12967-025-06689-8miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphomaHaixia Gao0Mengbo Wang1Shuchen Xiong2Ran Zhang3Cancan Wang4Huan Zhang5Wenli Ji6Cuicui Wang7Zhiying Jia8Xinxia Li9Departments of Pathology, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Ultrasound, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Pathology, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Pathology, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Pathology, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Pathology, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Pathology, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Pathology, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Ultrasound, The Affiliated Cancer Hospital of Xinjiang Medical UniversityDepartments of Pathology, The Affiliated Cancer Hospital of Xinjiang Medical UniversityAbstract Both miR-193a-3p and T-Cell Leukemia/Lymphoma 1 (TCL1) are enriched in the PI3K/AKT signaling pathway, which is pivotal for the regulation of the initiation and progression of diffuse large B-cell lymphoma (DLBCL). Although miR-193a-3p has been demonstrated to exert an inhibitory effect in various tumors, the relationship between miR-193a-3p and TCL1, as well as the mechanisms by which miR-193a-3p participates in the modulation of DLBCL onset and progression, remain to be elucidated. The expression levels of miR-193a-3p and TCL1 in DLBCL cells were examined using quantitative real-time polymerase chain reaction (qRT-PCR), and their impact on DLBCL cell growth was assessed through cell proliferation assays and flow cytometry. Subsequently, the interaction between miR-193a-3p and TCL1 was investigated using a dual-luciferase reporter assay. A nude mouse model of subcutaneous DLBCL was established in which the mice were injected with miR-193a-3p agomir, and were evaluated after 45 days. Finally, the mechanism by which miR-193a-3p modulates the PI3K/AKT signaling pathway was explored via qRT-PCR and Western blotting analyses. It was found that miR-193a-3p is downregulated, while TCL1 is upregulated in DLBCL. miR-193a-3p was shown to inhibit proliferation and induce apoptosis in DLBCL cells, in contrast to TCL1, which promotes proliferation and suppresses apoptosis. Moreover, TCL1 was identified as a target gene of miR-193a-3p. Additionally, it was demonstrated that miR-193a-3p regulates the PI3K/AKT signaling pathway through TCL1 both in vitro and in vivo. Collectively, these findings indicate that miR-193a-3p suppresses the growth of DLBCL by targeting TCL1 within the PI3K/AKT signaling pathway.https://doi.org/10.1186/s12967-025-06689-8miR-193a-3pTCL1PI3K/AKT signalling pathwayDiffuse large B-cell lymphoma
spellingShingle Haixia Gao
Mengbo Wang
Shuchen Xiong
Ran Zhang
Cancan Wang
Huan Zhang
Wenli Ji
Cuicui Wang
Zhiying Jia
Xinxia Li
miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma
Journal of Translational Medicine
miR-193a-3p
TCL1
PI3K/AKT signalling pathway
Diffuse large B-cell lymphoma
title miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma
title_full miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma
title_fullStr miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma
title_full_unstemmed miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma
title_short miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma
title_sort mir 193a 3p prevents tumour progression by targeting tcl1 in diffuse large b cell lymphoma
topic miR-193a-3p
TCL1
PI3K/AKT signalling pathway
Diffuse large B-cell lymphoma
url https://doi.org/10.1186/s12967-025-06689-8
work_keys_str_mv AT haixiagao mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT mengbowang mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT shuchenxiong mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT ranzhang mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT cancanwang mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT huanzhang mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT wenliji mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT cuicuiwang mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT zhiyingjia mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma
AT xinxiali mir193a3ppreventstumourprogressionbytargetingtcl1indiffuselargebcelllymphoma